Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study-Reference-Cited by-同舟云学术

Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study

Published:2006-03 Issue:3 Volume:28 Page:402-418
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Spencer Thomas J.,Abikoff Howard B.,Connor Daniel F.,Biederman Joseph,Pliszka Steven R.,Boellner Samuel,Read Stephanie C.,Pratt Raymond

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference30 articles.

1. Oppositional defiant and conduct disorder: A review of the past 10 years, part I;Loeber;J Am Acad Child Adolesc Psychiatry,2000

2. Children with oppositional defiant disorder. Facts for families. No. 72;American Academy of Child & Adolescent Psychiatry,2005

3. Diagnostic and Statistical Manual of Mental Disorders;American Psychiatric Association,2000

4. Conduct disorder and oppositional defiant disorder in a national sample: Developmental epidemiology;Maughan;J Child Psychol Psychiatry,2004

5. Parenting stress among families of children with attention deficit hyperactivity disorder;Anastopoulos;J Abnorm Child Psychol,1992

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Consensus international sur le dépistage, le diagnostic et le traitement des adolescents avec un trouble du déficit de l’attention avec ou sans hyperactivité en cas de comorbidité avec des troubles de l’usage de substances;Neuropsychiatrie de l'Enfance et de l'Adolescence;2023-01

2. Generalized structural equation modeling: Symptom heterogeneity in attention-deficit/hyperactivity disorder leading to poor treatment efficacy;World Journal of Psychiatry;2022-06-19

3. Muskelin regulates actin-dependent synaptic changes and intrinsic brain activity relevant to behavioral and cognitive processes;Communications Biology;2022-06-15

4. Impact of CNS Stimulants for Attention-Deficit/Hyperactivity Disorder on Growth: Epidemiology and Approaches to Management in Children and Adolescents;CNS Drugs;2021-07-23

5. Efficacy and Safety of Medication for Attention-Deficit Hyperactivity Disorder in Children and Adolescents with Common Comorbidities: A Systematic Review;Neurology and Therapy;2021-06-04